大摩:予上海医药(02607)“增持”评级 目标价降至17港元

Damo: Target price for Shanghai Pharmaceutical (02607) “gain” rating reduced to HK$17

Zhitong Finance ·  Apr 19 10:43

DamocaSea Pharmaceuticals (02607) lowered its 2024-2030 profit forecast by 2%-9%.

The Zhitong Finance App learned that Morgan Stanley released a research report stating that it lowered the target price of Shanghai Pharmaceuticals (02607) by 5.6%, from HK$18 to HK$17, and lowered the company's 2024-2030 profit forecast by 2%-9%. The main reason was the decline in sales in the manufacturing sector, but the rating still “increased”, mainly due to the complete integration of platforms (manufacturing, distribution, retail) to provide a synergy effect.

Damo's basic assumptions about the company are based on stable network expansion and valuable distribution agreements. Distribution sales growth remained low in double digits, and sales diversified, shifting from generic drugs to innovative drugs and vaccines, and strong business expansion outside hospitals, providing new options for large pharmaceutical companies.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment